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Background: Coronary heart disease (CHD) mortality rates have been decreasing in Turkey since the early 1990s.
Our study aimed to determine how much of the CHD mortality decrease in Turkey between 1995 and 2008 could
be attributed to temporal trends in major risk factors and how much to advances in medical and surgical
treatments.
Methods: The validated IMPACT CHD mortality model was used to combine and analyse data on uptake and
effectiveness of CHD treatments and risk factor trends in Turkey in adults aged 35–84 years between 1995 and
2008.
Data sources were identified, searched and appraised on population, mortality and major CHD risk factors for adults
those aged 35–84 years. Official statistics, electronic databases, national registers, surveys and published trials were
screened from 1995 onwards.
Results: Between 1995 and 2008, coronary heart disease mortality rates in Turkey decreased by 34% in men and
28% in women 35 years and over. This resulted in 35,720 fewer deaths in 2008.
Approximately 47% of this mortality decrease was attributed to treatments in individuals (including approximately
16% to secondary prevention, 3% angina treatments, 9% to heart failure treatments, 5% to initial treatments of
acute myocardial infarction, and 5% to hypertension treatments) and approximately 42% was attributable to
population risk factor reductions (notably blood pressure 29%; smoking 27%; and cholesterol 1%). Adverse trends
were seen for obesity and diabetes (potentially increasing mortality by approximately 11% and 14% respectively).
The model explained almost 90% of the mortality fall.
Conclusion: Reduction in major cardiovascular risk factors explained approximately 42% and improvements in
medical and surgical treatments explained some 47% of the CHD mortality fall. These findings emphasize the
complimentary value of primary prevention and evidence-based medical treatments in controlling coronary heart
disease.
Keywords: Coronary heart disease, Coronary heart disease mortality, Coronary heart disease risk factors,
Coronary heart disease management, Turkey, ModellingBackground
Turkey has a relatively young population compared to
many western societies. The total population was 75
million in 2008 and 30% were younger than 15 years of
age [1]. However, population structure is changing rap-
idly and Turkey has almost completed its demographic* Correspondence: belgin.unal@deu.edu.tr
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reproduction in any medium, provided the ortransition [2]. The median age of the population thus in-
creased from 22 years in 1990 to 27 years by 2008. The
proportion of those over 65 years of age was approxi-
mately 4% in 1990 and reached to 7% in 2008 [2]. The
ageing population and changes in lifestyle have contrib-
uted to increases in the burden of non-communicable dis-
eases (NCDs) [3].
Coronary heart disease (CHD) is the major cause of
death and disability in Turkey. In the Turkish National
Burden of Disease Study (2000) CHD and cerebrovasculard. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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deaths [3].
In most industrialized countries, CHD mortality rates
have decreased considerably since the 1970s [4]. Decreases
started some 10–15 years later in middle income countries
[4]. Thus in a recent analysis of CHD mortality rates in
Turkey, increasing trends were observed from 1988 (366
per 100000) to 1994 (411 per 100000) but then decreasing
from 1995 to reach (348 per 100000 in 2008) [5]. How-
ever, the underlying factors associated with this significant
decrease in CHD mortality have not been comprehen-
sively evaluated.
Previous studies in some high income countries have
shown that improvements in major cardiovascular risk
factors, including total cholesterol, blood pressure levels
and smoking, explain a greater proportion of the mortal-
ity decline than treatments, ranging from 44% in the
USA to 72% in Finland [6-8]. This principally reflects
improvements in smoking and modifiable dietary risk
factors [6-8]. However few such studies have been per-
formed in middle or low income countries.
The information on CHD prevalence, incidence and
determinants of CHD in Turkey is rapidly improving.
There are several ongoing studies from the Turkish Cardi-
ology Association [9], the Turkish Society of Hypertension
and Renal Disease [10,11], the Turkish Endocrinology
Association (TURDEP) [12,13] and from the Universities
[14-17]. These together provide increasing good trend
data on cardiovascular risk factors.
Thus, in Turkey, recent population studies document
significant decreases in population blood pressure, chol-
esterol [18,19] and smoking prevalence [20]. However,
obesity and diabetes prevalence are now increasing
steeply [13,21,22] as in most other developed and devel-
oping countries.
Approximately 25%-55% of the recent CHD mortality
declines in developed countries have been attributed to
the use of evidence-based medical and interventional
therapies [7,8,23,24]. These include aspirin, beta-blockers,
ACE-inhibitors and angiotensin-receptor-blockers (ARBs),
statins, fibrinolysis, percutaneous coronary intervention
(PCI) and coronary artery bypass surgery (CABG) [7,25].
In Turkey, treatment uptake in CHD patients has in-
creased substantially since the 1990s [26,27].
Our objective was therefore to study recent trends in
CHD deaths between 1995 and 2008, using a previously
validated epidemiological model, to determine the con-
tribution of prevention and treatment strategies.
Methods
We used an updated version of the IMPACT CHD mor-
tality model that was originally developed in Scotland
and then validated in many countries including England,
New Zealand, United States, Canada, Europe and China[7,24,28-30]. Data on risk factor levels and current up-
take levels of evidence based medical and surgical treat-
ments were identified by extensive search of published
and unpublished data and complemented with specifically
designed surveys. All data sources were critically appraised
by the research team and the results are presented in
Additional file 1: Table S1.
The IMPACT model was populated with data for men
and women aged 35–84 (in 10 year age groups) for both
1995 and 2008. The main data items included data on: a)
population sizes in each year, by age group and gender; b)
Patient numbers in specific CHD groups (Myocardial
Infarction, Congestive Heart Failure, Chronic Angina Pec-
toris, c) uptake levels of specific medical and surgical
treatments, (Table 1), and d) population trends in major
cardiovascular risk factors (smoking, total cholesterol, sys-
tolic blood pressure, body mass index, diabetes, physical
inactivity and fruit and vegetable consumption) (Table 2).
The number of CHD deaths attributable to each specific
treatment and risk factor were calculated for 1995 and for
2008. The difference between the two values then repre-
sented the deaths prevented or postponed (DPP) attrib-
uted to the change in risk factors and treatment uptake
levels in the population.
Information on population and demographic changes
were obtained from the census (1995) and Address Based
Population Registration System (2008) of the Turkish Stat-
istical Institute [1]. Although the data collection method
changed from 1995 to 2008, population projections based
on the census are very close to the population of address
based registration in 2008 [31].
The numbers of CHD deaths were estimated using
mortality statistics from the Turkish statistical institute
Data on cause of death was collected only from urban set-
tings which comprised approximately 50%-68% of the
total population over the years 1988–2008 [1]. Therefore,
the total number of deaths was estimated by inflating the
urban deaths proportional to the rural population simply
assuming that a similar mortality pattern existed in rural
areas [3]. The total number of deaths was also inflated by
12% in men and 16% in women to account for underre-
porting of the deaths based on expert opinion [3]. The
numbers of CHD deaths by age and sex groups for 1995
and 2008 were obtained from the Turkish Statistical Insti-
tute coded according to International Classification of
Diseases, 8thRevision (corresponds to ICD9 codes 410–
414) based on final cause of death [1]. Coding inaccuracy
is an important limitation of the mortality data in Turkey
[32]. Ill defined codes and the “other heart diseases” codes
accounted for approximately 30 to 40% of the total deaths
during the study period [32]. Therefore, 50% of the “other
heart disease” group were allocated to CHD deaths
through the study period [3] .
Table 1 Estimated deaths prevented or postponed by medical or surgical treatments in Turkey in 2008
Number of deaths prevented
or postponed
Percentage of total
reduction
Treatments Number of
eligible patients
Patients receiving
treatment (%)
Relative risk
reduction (%)
Mean case-
fatality (%)
Absolute risk
reduction
Best
estimate
Minimum
estimate
Maximum
estimate
Best
estimate
Minimum
estimate
Maximum
estimate
Acute MI 91317 0.067 1677 684 3309 4.7 1.9 9.3
Community CPR 9132 100 0.05 0.067 0.055 443 283 638 1.2 0.8 1.8
Hospital CPR 2740 6 0.32 0.067 0.323 53 34 91 0.1 0.1 0.3
Thrombolysis 91317 29 0.26 0.067 0.014 316 130 656 0.9 0.4 1.8
Aspirin 91317 93 0.15 0.067 0.010 774 317 1420 2.2 0.9 4.0
Beta blocker 91317 70 0.04 0.067 0.003 143 59 296 0.4 0.2 0.8
ACE inhibitor 91317 61 0.07 0.067 0.005 228 93 466 0.6 0.3 1.3
Primary PTCA 91317 18 0.32 0.067 0.020 589 241 1221 1.6 0.7 3.4
Primary CABG 91317 9 0.20 0.067 0.013 112 40 231
MI treatments in 1995 subtracted −1244 −599 −2367 3.5 1.7 6.6
Unstable angina 639 364 1800 1.8 1.0 5.0
Aspirin & heparin 45658 50 0.33 0.053 0.017 316 129 655 0.9 0.4 1.8
Aspirin alone 45658 88 0.15 0.053 0.008 245 100 465 0.7 0.3 1.3
PG IIB/IIIA 45658 41 0.09 0.053 0.005 70 28 144 0.2 0.1 0.4
CABG surgery for UA 45658 13 0.43 0.053 0.023 107 44 221 0.3 0.1 0.6
PTCA for UA 45658 26 0.32 0.053 0.016 152 62 314 0.4 0.2 0.9
Secondary Prev Post AMI 759071 0.061 4548 1454 6509 12.7 4.1 18.2
Aspirin 759071 73 0.778 0.045 0.007 2170 711 3665 6.1 2.0 10.3
Beta blocker 759071 63 0.526 0.045 0.010 2052 672 3713 5.7 1.9 10.4
ACE inhibitor 759071 61 0.514 0.045 0.009 1771 580 3198 5.0 1.6 9.0
Statin 759071 3 0.757 0.045 0.010 1339 351 2767 3.7 1.0 7.7
Warfarin 759071 8 0.032 0.045 0.010 76 25 138 0.2 0.1 0.4
Secondary Prev Post CABG/PCI 275652 0.006 1752 575 4164 4.9 1.6 11.7
Aspirin 273379 97 0.15 0.017 0.003 496 162 1076 1.4 0.5 3.0
Beta blocker 273379 60 0.23 0.017 0.004 470 154 1167 1.3 0.4 3.3
ACE inhibitor 273379 54 0.20 0.017 0.003 366 120 909 1.0 0.3 2.5
Statin 273379 87 0.22 0.017 0.004 377 124 898 1.1 0.3 2.5
Warfarin 273379 2.2 0.22 0.017 0.004 18 6 44 0.1 0.0 0.1
Rehabilitation 273379 83 27 208 0.2 0.1 0.6
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Table 1 Estimated deaths prevented or postponed by medical or surgical treatments in Turkey in 2008 (Continued)
Chronic angina 3348 1105 8627 9.4 3.1 24.2
CABG surgery 1995-2008 103293 100 0.35 0.012 0.002 632 324 1093 1.8 0.9 3.1
CABG treatments in 1995 subtracted 103293 −6 −4 −8 0.0 0.0 −0.1
Angioplasty 1996-2000 103293 100 0.00 0.022 0.000 0 0 0 0.0 0.0 0.0
Aspirin in community 103293 78 0.15 0.012 0.001 2840 931 7066 8.0 2.6 19.8
Statins in community 103293 63 0.23 0.012 0.003 1517 398 4530 4.2 1.1 12.7
Hospital heart failure 46511 0.258 1025 306 2756 2.9 0.9 7.7
ACE inhibitor 46511 43 0.20 0.166 0.033 251 66 744 0.7 0.2 2.1
Beta blocker 46511 37 0.35 0.166 0.058 378 99 1121 1.1 0.3 3.1
Spironolactone 46511 40 0.30 0.166 0.051 510 167 1269 1.4 0.5 3.6
Aspirin 46511 68 0.15 0.166 0.025 428 140 1041 1.2 0.4 2.9
Community heart failure 424611 0.085 2338 747 5961 6.5 2.1 16.7
ACE inhibitor 70 0.20 0.085 0.013 479 126 1430 1.3 0.4 4.0
Beta blocker 70 0.35 0.085 0.030 986 323 2453 2.8 0.9 6.9
Spironolactone 25 0.31 0.085 0.030 883 289 2197 2.5 0.8 6.1
Aspirin 90 0.15 0.085 0.013 924 303 2299 2.6 0.8 6.4
Statins 40 0.00 0.085 0.000 0 0 0 0.0 0.0 0.0
Hypertension treatment 10029567 57 0.13 0.007 0.001 2153 356 4472 6.0 1.0 12.5
Statins for primary prevention 6133187 2 0.35 0.006 0.002 41 11 205 0.1 0.0 0.6
Total treatment 16671 5356 35362 47.0 15.1 100.0
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Table 2 Deaths from coronary heart disease prevented or postponed as a result of changes in population risk factors in Turkey, 1995-2008
Risk factor Number of eligible
patients
Absolute
level of
risk factors
Change in risk
factors
Beta
regression
coefficient for
change in
mortality rate
Relative
risk
Deaths prevented or posponed
1995 2008 Absolute
change
Relative
change (%)
Number of deaths Percent of total reduction
Best
estimate
Minimum
estimate
Maximum
estimate
Best
estimate
Minimum
estimate
Maximum
estimate
Smoking prevalence, % 27186380 27.0 16.0 −11.0 −36.1 9724 7779 11669 27.2 21.8 32.7
Men 13497080 44.4 24.6 −19.8 −45.5 2.52 8377 6702 10053 48.8 39.0 58.6
Women 13689300 9.4 7.2 −2.2 −27.2 2.14 1347 1077 1616 7.3 5.8 8.7
Systolic BP, mmHg 27186380 127.3 124.6 −2.8 −2.0 13549 8889 18937 37.9 24.9 53.0
Men 13497080 124.1 123.3 −0.7 −0.0 −0.033 3579 2318 5081 15.8 10.3 22.5
Women 13689300 130.2 125.8 −4.4 −3.5 −0.041 9970 6572 13855 55.9 36.8 77.6
Population BP after adjustment for
hypertension treatments
10363 8263 12990 29.0 23.1 36.4
Total cholesterol, mmol/L 27186380 4.96 4.97 0.01 0.01 −354 −226 −510 −1.0 −0.6 −1.4
Men 13497080 4.91 4.92 0.01 0.01 −0.627 −200 −128 −288 −0.0 0.0 0.1
Women 13689300 5.02 5.03 0.01 0.01 −0.619 −154 −99 −222 −0.0 0.0 0.1
Population TC after adjustment for
antilipidemic treatments
−395 −237 −715 1.1 0.7 2.0
BMI, kg/m2 27186380 27.4 29.0 1.59 6.0 −3790 −2149 −5784 10.6 6.0 16.2
Men 13497080 26.1 27.9 1.80 7.0 0.028 −2117 −1202 −3227 12.3 7.0 18.8
Women 13689300 28.7 30.1 1.37 5.0 0.028 −1673 −947 −2557 9.0 5.1 13.8
Diabetes prevalence, % 27186380 15.5 18.7 3.2 18.7 −5086 −4069 −6103 −14.2 11.4 17.1
Men 13497080 14.5 17.5 3.0 20.4 1.93 −1866 −1493 −2240 −10.9 8.7 13.0
Women 13689300 16.4 19.9 3.4 17.2 2.59 −3220 −2576 −3864 −17.4 13.9 20.8
Physical inactivity 27186380 70.0 65.0 −5.0 −7.0 1919 1535 2303 5.4 4.3 6.4
Mean Fruit&Vegetable consumption in
portions
27186380 3.2 3.5 32.0 10.0 0.041 2377 475 4974 6.7 1.3 13.9
Total risk factors 15112 11597 19333 42.3 32.5 57.3
BMI = weight [kg]/height [m]2.
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For the base year of 1995 were obtained from national
representative surveys TEKHARF [9], TURDEP [12] sup-
plemented with regional studies [15,33-35]. For the later
years more national surveys became available [15-17].
The main data sources for major risk factors are pre-
sented in Additional file 1: Table S2.The numbers of hospital admissions for CHD
Were estimated using the Ministry of Health (MoH)
hospital admission data [36] and from two cohort stud-
ies [37,38]. The number of patients undergoing Coron-
ary Artery Bypass Grafting (CABG) and angioplasty
were obtained from the MoH hospital admission data
supplemented with information by experts from the
Turkish Cardiology Association and Cardiovascular Surgery
Association, emergency physicians and family physicians.
In total 10 experts were initially contacted individually and
sent a questionnaire asking their opinions on number of
hospital admissions and treatment uptakes for CHD patient
groups. Following this they were invited to participate a
consensus meeting with other experts. Treatment uptake
levels for initial CHD treatments in the hospital were
obtained from the hospital survey designed by the re-
search team in the Dokuz Eylul University Hospital and
studies published on treatment uptake in the emergency
department [39].
The prevalence of angina, post myocardial infarction
patients and congestive heart failure in the community
was estimated based on representative population surveys
including the National Household Survey [3] and Health
Surveys 2008 and 2010 [40,41].
Information on treatment uptake in the community
was based on PREMISE [27], EUROASPIRE III [26] and
population based studies [14,42,43].The efficacy of specific therapeutic interventions
Was based on recent meta-analyses and randomised con-
trolled trials (Additional file 1: Table S4). The potential ef-
fect of multiple treatments in an individual patient was
quantified using the Mant and Hicks cumulative relative
benefit approach [44] as detailed in Additional file 1.Change in CHD Deaths between 1995 and 2008
The number of CHD deaths expected in 2008 assuming
that mortality rates in 1995 persisted to 2008 was calcu-
lated by indirect age standardization. The CHD deaths
actually observed in 2008 were then subtracted to quan-
tify the decrease in CHD deaths between 1995 and 2008.
These represent the number of deaths prevented or post-
poned (DPPs) between 1995 and 2008 which the model
needs to explain.The mortality changes attributed to risk factor trends
The DPPs from changes in risk factors were estimated
using two approaches: The regression β coefficient ap-
proach was used to quantify the population mortality
impact of change in those specific risk factors, measured
as continuous variables, (systolic blood pressure, total
cholesterol and BMI). The mortality reduction was then
estimated as the product of the CHD deaths observed in
1995 (the baseline year), the subsequent reduction in
that risk factor and the regression coefficient that quan-
tified the change in CHD mortality expected per unit of
absolute change in the risk factor. The sources of regres-
sion were presented in Additional file 1: Table S5.
The second approach, population attributable risk
fraction(PAR) was used for categorical variables- smok-
ing, diabetes, physical inactivity and fruit and vegetable
consumption using Levin’s equation:
PAR ¼ Prevalence Relative Risk−1ð Þ
Prevalence Relative Risk−1ð Þ þ 1½ 
Details of the model methodology have been published
previously [7,33] and are illustrated in Additional file 1.
Estimating the contribution of medical and surgical
treatments
The model included all medical and surgical treatments
in 1995 (the base year) and 2008 (the final year). Treat-
ment uptake data was limited for the year 1995 and thus
much of the data included in the model for this year was
estimated based on opinion of cardiology experts from
Dokuz Eylul University (Additional file 1: Table S2).
The treatment arm of the model consisted of mutually
exclusive CHD subgroups: patients hospitalized within
the last year for an acute myocardial infarction (AMI),
or for unstable angina pectoris or heart failure due to
ischemic cardiomyopathy, community-dwelling patients
who were post-AMI survivors, patients with chronic an-
gina, patients receiving revascularisation CABG surgery
or angioplasty, patients with heart failure in the commu-
nity and, finally, hypertensive and hypercholesterolemia
individuals eligible for primary prevention with lipid
lowering therapy.
The mortality reduction for each treatment within each
patient group was then calculated as the product of:
The number of patients in that group, their age-specific
case fatality, the patient uptake (the proportion receiving
that specific treatment) and treatment efficacy (the relative
mortality reduction reported in published meta-analyses
and trials) Additional file 1.
Case-fatality data were obtained from large, unselected,
population-based patient cohorts [45,46]. Survival benefit
over a one-year time interval was used for all treatments
[47] stratified by age and sex.
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Potential overlaps between different groups of patients
were identified and appropriate adjustments were made.
Patients group calculations and assumptions are detailed
in Additional file 1.
Adherence or the proportion of treated patients actu-
ally taking therapeutically effective levels of medication,
was assumed to be 100% in hospital patients, 70% in
symptomatic community patients, and 50% in asymp-
tomatic community patients based on the available lit-
erature [48].
Sensitivity analyses
Because of the uncertainties surrounding many of the
values, a multi-way sensitivity analysis was performed
using the analysis of extremes method [49]. For each
model parameter, a maximum and minimum feasible
value was assigned using the 95% confidence intervals
from the source documentation when this was available.
We otherwise robustly defined these limits as 20% above
and below the best estimate (for the number of patients,
use of treatment, compliance and case fatality).
Validation: comparison of model estimates with observed
mortality falls
The model estimates for the total number of deaths pre-
vented or postponed by each treatment and each risk
factor change were summed and compared with the ob-
served changes in mortality for men and women in each
age group. Any shortfall in the overall model estimate
was then presumed to be attributable either to inaccur-
acies in our model estimates or to other, unmeasured
risk factors [7,24,28]. The study protocol was approved
by the Izmir Clinical Research Ethics Commitee (Deci-
sion no:09-9/15 Date:07.09.2009)
Results
Between 1995 and 2008, age-adjusted CHD mortality rates
in Turkey fell 34% in men (from 455.9 to 365.7 per 100 000
aged 35–84 years) and 28% in women (from 378.6 to 324.5
among women aged 35–84 years). In 1995, there were
79,065 deaths among this age group due to CHD. In 2008,
a total of 96,365 CHD deaths were recorded representing
35,720 fewer CHD deaths than expected if the baseline
mortality rates in 1995 had persisted.
Overall, the Turkish IMPACT model was able to ex-
plain approximately 31,785 (89%) of the 35715 mortality
decrease between 1995 and 2008. The remaining 11%
was attributed to changes in other, unmeasured factors.
Medical and surgical treatments
Improvements in medical and surgical treatments be-
tween 1995 and 2008 prevented or postponed approxi-
mately 16,670 CHD deaths (minimum estimate 5355,maximum estimate 35360 Table 1, Figure 1) represent-
ing approximately 47% of the overall CHD mortality
reduction.
The most substantial contributions came from the im-
proved treatment of post AMI patients (approximately
4550 fewer deaths; 13% of total; minimum estimate 1455,
maximum estimate 6509) Aspirin, Beta blockers, ACE in-
hibitors and Statins each provided similar benefits.
Secondary prevention following revascularisation had
a modest effect on CHD mortality reduction with a con-
tribution of 5% (minimum 1.6% and maximum 11.6%).
The second largest contribution came from chronic an-
gina treatments (a total reduction of approximately 3350
deaths, representing some 9% of total mortality reduction).
Heart failure treatments in the community and imme-
diate treatments for AMI and unstable angina each ex-
plained approximately 6% of the mortality fall. Primary
PTCA used in treatment for AMI was associated with a
relatively modest reduction in mortality, saving approxi-
mately 590 lives and representing approximately 1.6% of
the total.
Small mortality reductions were also explained by the
treatments for hypertension (5%) and statins in primary
prevention (4%) and heart failure treatments in the hos-
pital (3%) (Table 1).
Major cardiovascular risk factors
Changes in major cardiovascular risk factors together
explained approximately 15,110 CHD deaths prevented
or postponed (minimum estimate 11595, maximum esti-
mate 19335) (Table 2), representing approximately 42%
of the CHD mortality fall between 1995 and 2008. The
largest reduction in deaths was explained by substantial
reductions in population blood pressure levels, from
127.2 mmHg in 1985 to 124.6 mmHg in 2008, a relative
decrease of 2%. After accounting for the 3185 fewer
deaths attributable to primary prevention with hyperten-
sion treatments, we estimated that approximately 10,365
CHD deaths were prevented or postponed due to reduc-
tions in mean blood pressure from life-style and dietary
changes from 1995 to 2008, representing some 29% of the
overall reduction in CHD mortality (Figure 1, Table 2).
Reductions in smoking prevalence in men (−46%) and
in women (−27%), also explained approximately 9725
fewer CHD deaths overall.
Population mean cholesterol did not change signifi-
cantly in Turkey between 1995 and 2008, a 0.02% in-
crease in the population mean cholesterol levels resulted
in some 355 deaths. Statin treatments for primary pre-
vention in people with high cholesterol prevented or
postponed approximately 725 deaths.
The effects of a decrease in physical inactivity preva-
lence and increase in fruit and vegetable consumption
prevented or postponed approximately 1920 and 2375
Figure 1 Coronary heart disease deaths prevented or postponed by treatment and risk factors changes in the Turkey population
between 1995 and 2008.
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deaths respectively (Table 2).
However, there were adverse trends in diabetes preva-
lence and BMI levels between 1995 and 2008. Diabetes
prevalence increased from 14.5 to 17.5% in men and
16.4% to 19.9% in women (20% and 17% relative increases)
from 1995 to 2008, which resulted in approximately 1865
deaths in men and 3220 additional deaths in women
representing some 14% of the total deaths. Increases in
mean BMI (7.0% in men and 5.0% in women) generated
approximately 3790 additional deaths, which effectively
represents an additional 10% (minimum 6.0% and max-
imum 16.2%) to total CHD deaths (Table 2).
Sensitivity analysis and proportional contributions to the
decrease in deaths
Sensitivity analyses suggested some uncertainty surround-
ing the risk factor best estimate contribution of 42%, with
a range from 33% to 54% (Tables 1 and 2). There was a
larger uncertainty in our estimates of the treatment con-
tribution (best estimate 47% - minimum15%, maximum
99%). However, the proportional contributions of specific
treatments and risk factor changes to the overall decrease
of CHD mortality in Turkey between 1995 and 2008
remained relatively consistent, irrespective of whetherbest, minimum or maximum estimates were used (Tables 1
and 2).
Discussion
In Turkey, CHD mortality rates fell by 31% between
1995 and 2008 which is similar to the falls reported in
affluent Western countries, including England and Wales
[7], Ireland [30], Sweden [50] and Italy [51], since the
1980s but occurring later in Turkey.
Approximately 47% of this mortality fall was attribut-
able to the combined effects of modern cardiological
treatments and almost 42% was attributable to reduction
in major risk factors, particularly smoking and blood
pressure. In the previous modelling studies more than
half of the fall was explained by risk factor reductions in
England and Wales [7], Ireland [30], in Sweden [50],
Italy [51]. Modern cardiological treatments together pre-
vented or postponed approximately 16,700 deaths in
2008 in Turkey. Irrespective of whether best, minimum
or maximum estimates were used, the most substantial
contributions came from secondary prevention and an-
gina treatments.
Revascularisation from CABG surgery and angioplasty
together accounted for barely 4% of the total mortality
fall, much as in the USA [24] and other countries [7].
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when considering the large financial and political re-
sources being consumed [52].
Thrombolysis, likewise, only accounted for approxi-
mately one fifth of the deaths prevented in the initial
treatments for acute myocardial infarction. Aspirin and
cardiopulmonary resuscitation contributed far more, simi-
lar to other studies [7].
Furthermore, treating angina patients with aspirin in
the community prevented almost four times as many
deaths as treating unstable angina patients in hospitals,
mainly reflecting the far greater numbers of patients eli-
gible for this treatment (Table 1).
Treatment uptake levels were often poor, especially for
beta blockers and ACE inhibitors for secondary preven-
tion (Table 1). Earlier work in the UK suggested that if
80% of eligible patients had received appropriate therapy,
approximately 30,000 additional deaths might have been
prevented or postponed each year in the UK [53]. The
same powerful principle would clearly apply in Turkey.
Reductions in the major risk factors between 1995 and
2008 accounted for approximately 15100 fewer deaths in
Turkey in 2008. The biggest single contribution, 38%,
reflected a 2.74 mmHg absolute decline in systolic blood
pressure. The improvements in blood pressure are con-
sistent with improvements in diet rather than treatment.
Turkish diet is traditionally rich in fresh fruit and vege-
tables, legumes and unsaturated fat. Since the socioeco-
nomic improvements in the 1990s, more people are now
able to afford fresh fruit and vegetables rather than
consuming preserved food that contain substantial salt.
However, a recent national survey suggests that daily salt
consumptions still very high, approximately 18 gr per
day [54]. Traditionally, salt is widely used in pickles, ol-
ives, dairy products and bread which together constitute
a major part of the Turkish diet. Future population
based salt reduction strategies may achieve substantial
further blood pressure reductions.
Almost 27% of the mortality fall came from a 41%
relative reduction (from 26.5% to 16%) in male smoking.
However, smoking prevalence did not change significantly
in women. The National Tobacco Control Programme
which began in 2008, may further accelerate this decreas-
ing trend in Turkey [55]. The programme aims to increase
awareness of the damaging health effects of smoking, to-
gether with the government anti-smoking measures in-
cluding taxation, banning smoking in the public places,
intensified anti-smoking campaigns, and the banning of
advertising [55].
The adverse trends in obesity and diabetes together
contributed over 9000 additional deaths in 2008. This
therefore cancelled out much of the benefits attained by
the decreases in blood pressure and smoking prevalence
during the same period. Obesity and diabetes trends arealarming both in men and women in Turkey [12,13]
with major concerns about future continuing deteriora-
tions [56]. New diabetes and obesity control programs
were prepared for the period of 2010–2014 [57,58] but
these will need to be implemented aggressively to have
any benefit.
Population mean cholesterol did not change signifi-
cantly in Turkey between 1995 and 2008. Stable trends
or only small decreases in cholesterol levels were also
observed in several other Eastern European countries in-
cluding Tunisia and Iran [19].
Modelling strengths and limitations
Models are potentially useful tools for policy develop-
ment. They integrate and simultaneously consider huge
amounts of data from many different sources. On the
other hand, they are very dependent on the quality and
extent of data available on CHD risk factor trends and
treatment uptakes [59,60].
The data used in the Turkish IMPACT model was
generally of good quality. Mortality data was obtained
from the Statistical Institute of Turkey (TURKSTAT)
which has a long experience of death registry since 1930
[1]. Although the cause of death statistics were based on
only urban area and the rates were estimated assuming
similar death patterns exist in rural population, our esti-
mates for year 2000 were similar with National Burden
of Disease Study. The declining CHD mortality trend
starting from the mid 1990s is thought to be real since
there were no operational changes in the death reporting
system over that time period. Data quality indicators
such as the proportion of ill defined codes (symptoms/
senility or other heart disease) have remained consistent,
which also supports this finding. During the entire
period (1995to 2008) the proportion of senility, symp-
toms and other heart disease codes were relatively stable
in men and women (ranging from 43-53% and 52-63%,
respectively) (Data are available upon request from the
authors). The demographic information was obtained
from the census data that covered whole country, the
risk factor trends were obtained from national epi-
demiological studies. Treatment uptake data was ob-
tained from multicentre national studies (EUROASPIRE
III [26], PREMISE [27]) and from a hospital based sur-
veys conducted in recent years [43,61,62]. Certain as-
sumptions were therefore taken to fill in the gaps for
missing information including specific patient groups’
data. These assumptions are systematically detailed in
the Additional file 1, and were supported by local expert
opinions and literature from the region and included in
the sensitivity analysis. In the Turkish IMPACT model,
we assessed the potential maximum and minimum
plausible effects of these factors using rigorous sensitiv-
ity analyses which systematically examined the influence
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Our study has several potential limitations. The model
included only those adults aged 35 to 84 years, because
of very limited data in older age groups. The efficacy
data were derived from clinical trials and may have overes-
timated effectiveness in usual clinical practice. We consid-
ered only deaths from CHD, and ignored “competing
causes” such as cancer. However, the reductions in smok-
ing would actually have decreased deaths from lung
cancer and some other cancers [63]. Finally, the lag times
were not explicitly considered in this model assuming that
substantial mortality reduction occurs within 1 to 4 years
of quitting smoking or reducing cholesterol [64-66].
This is the first comprehensive modelling study that
examines the impact of changes in population risk fac-
tors and effective treatments on CHD mortality trends
in Turkey. The Ministry of Health developed policy doc-
uments and action plans to tackle the growing NCD
problem [55,57,58,67]. The Ministry of Health also coor-
dinated the development of national guidelines for CHD,
hypertension and diabetes control. This model can be a
useful tool to explore potential benefits of implementing
certain strategies to prevent the future CHD.
Conclusions
Coronary heart disease mortality in Turkey fell by more
than 30 percent between 1995 and 2008. Approximately
half of this decline was explained by treatments. How-
ever, although changes in major risk factors, mainly
smoking and blood pressure potentially explained over
half of the decline, much of these benefits were then ne-
gated by worrying increases in obesity and diabetes. Our
findings thus emphasize the value of primary prevention
strategies targeting the whole population including healthy
diet and tobacco control, plus evidence-based medical
treatments for our patients in Turkey.
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